TCT 2017: Fewer Stents Are Better Than More For Initial AMI-With-Shock Treatment
Executive Summary
Results of the CULPRIT-SHOCK trial presented at the Transcatheter Cardiovascular Therapeutics conference in Denver confirm that patients with acute myocardial infarction complicated by cardiogenic shock are better off treated with culprit-lesion-only percutaneous coronary intervention rather than multivessel stenting, which is currently recommended in the European guidelines.
You may also be interested in...
Lawyers Seek Clients For Possible Securities Fraud Case Against Dentsply Sirona
An internal investigation found that the company’s leadership may have directed employees to improperly account for sales-incentive payments. As a result, the company has been unable to file its quarterly report for the first quarter of 2022 with the SEC.
Vince Burgess Steps Down After Nine Years As Acutus CEO
Analysts believe the company’s arrythmia mapping technology could potentially disrupt the electrophysiology mapping market, but are disappointed with Acutus’ growth so far.
Exec Chat: As Reimbursement Questions Get Answers, iRhythm Looks To The Future
Medtech Insight caught up again with iRhythm CEO Quentin Blackford about his vision for the company as it plans for the next five to ten years of expansion in the remote cardiac monitoring and arrhythmia diagnostics market.